PharmAthene, Inc. [PIP] has completed its acquisition of the biodefense vaccines business unit from the United Kingdom's Avecia Biologics in a deal that bolsters its portfolio of anthrax vaccine capabilities and gives it a potential product for plague vaccine. Terms of the deal include a $10 million cash payment and additional $7 million to be paid within 18 months of the closing. Avecia will also be able to receive payments up to $23 million contingent upon the achievement of certain…
Recommended
Navy, Marine Corps Experimenting With Large Scale Advanced Manufacturing Network During RIMPAC
Trending
Congress Updates
CBO Says Upfront Costs To Protect Military Installations From Drones Between $1 Million And $74 Million
The initial costs to acquire and deploy counter-small unmanned aircraft system (C-sUAS) defenses at individual Defense Department installations are estimated at between $1.2 million and $73.6 million depending on the […]
House Heads For Recess Without Moving On NDAA After Procedural Vote Fails
The House will leave for the Fourth of July recess without moving forward on its $1.15 trillion fiscal year 2027 National Defense Authorization Act (NDAA), with a procedural vote to […]
Bipartisan Group Of House Members Introduce U.S.-Ukrainian Co-Production Bill For Unmanned Systems
A bipartisan group of six House legislators have introduced the Strategic Unmanned Systems Partnership Act–a bill to improve drone collaboration between the U.S. and Ukraine. Rep. Michael McCaul (R-Texas), the […]
Will $4 Billion For SB-AMTI/Space Data Network Backbone In Supplemental Reduce Or Add To Planned Funding For Systems In Reconciliation?
Nearly all of the Department of the Air Force’s fiscal 2027 procurement and research and development (R&D) budget for space-based air moving target indication (SB-AMTI) and the Space Data Network […]